ImmunoPrecise Antibodies Ltd. (IPA)
| Previous Close | 0.3470 |
| Open | 0.3484 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3300 - 0.4000 |
| 52 Week Range | 0.3250 - 2.6000 |
| Volume | |
| Avg. Volume | 522,687 |
| Market Cap | 10.841M |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7700 |
| Earnings Date | Dec 12, 2024 - Dec 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Business Wire$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
VICTORIA, British Columbia, November 13, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA’s cutting-edge discovery and AI capabilities, but it also strategically places the company in the rapidly growing market for these cancer-combating antibodies, which is projected to reach $20.7 billion by
Business WireImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
VICTORIA, British Columbia, November 04, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA’s latest advancements in AI-driven design, biologics innovation, and strategic technological developments.
